Table 2 Metabolic biomarkers in predicting MAFLD.

From: Metabolic biomarkers related to cardiac dysfunction in metabolic-dysfunction-associated fatty liver disease: a cross-sectional analysis

Metabolite

AUC

T-tests

Total (n = 75)

MAFLD (n = 38)

Controls (n = 37)

P-value

Glycyl tyrosine, median (IQR)

0.802

0.063

0.274 (0.212–0.325)

0.216 (0.197–0.274)

0.323 (0.272–0.358)

<0.001

LPC (18:2/0:0), median (IQR)

0.774

2.149

1.953 (0.983–3.261)

1.033 (0.364–1.597)

3.262 (2.613–4.028)

<0.001

LPC (22:6), median (IQR)

0.745

1.492

1.716 (0.972–3.061)

1.039 (0.596–1.47)

2.809 (1.669–3.432)

<0.001

Cer (d18:0/23:0), median (IQR)

0.775

1.197

1.769 (1.382–2.66)

1.323 (1.012–1.769)

2.183 (1.648–3.462)

0.003

  1. AUC area under the Receiver Operating Curve, Cer ceramide, IQR interquartile range, LPC lysophosphatidylcholine, MAFLD Metabolic-dysfunction-associated fatty liver disease.
Back to article page